Curesign

Know sooner whether cancer treatment is working.

Curesign is building AI software that turns routine ultrasound into an objective, repeatable measure of how a tumor responds to treatment. Oncologists can follow the change from one visit to the next, rather than waiting for the next scheduled MRI or CT.

See how it works Contact us
Illustration of an ultrasound image with a tissue-stiffness map highlighting a tumor

Treatment moves quickly. Response imaging doesn't.

Whether a cancer therapy is working is judged mainly with MRI and CT. Both are accurate, but they are expensive, hard to schedule and impractical to repeat often, so they are usually weeks apart. In the meantime, a patient whose tumor isn't responding may stay on a treatment that isn't helping them.

Ultrasound is the opposite. It is low-cost, involves no radiation and is available in almost every hospital. What has held it back in cancer care is consistency: the result depends on who holds the probe and how they read the image, which makes one visit hard to compare with the next.

Scheduled MRI or CT
Ultrasound measured by Curesign
Treatment startsCourse of treatment
Illustrative. Measuring at every visit gives the care team feedback on a treatment while there is still time to change it.

Ultrasound, made measurable

Curesign's software analyzes a standard ultrasound examination that captures both the shape of a tumor and the stiffness of its tissue. It measures the tumor the same way at every visit and compares each new scan with the ones before, so a change over time reflects the tumor, not the person doing the scan.

  1. Illustrated tumor at visit 1, largest and stiffestVisit 1
  2. Illustrated tumor at visit 2, slightly smallerVisit 2
  3. Illustrated tumor at visit 3, smaller and softerVisit 3
  4. Illustrated tumor at visit 4, smallest and softestVisit 4
Illustration: one tumor followed across four visits, getting smaller and softer as treatment takes effect.Softer Stiffer

Objective

Size and tissue stiffness are measured automatically and reported as numbers, not impressions.

Comparable

Each scan is lined up with the patient's earlier scans, so change between visits is measured directly.

Accessible

Software only, built on ultrasound that hospitals already use. No radiation, so scans can be repeated as often as care needs.

How it fits into care

  1. Scan

    During a routine visit, a sonographer performs one standard ultrasound examination.

  2. Measure

    The scan is analyzed automatically. Curesign measures the tumor and compares it with the patient's previous scans.

  3. Decide

    The oncologist gets a clear visual report of how the tumor is changing, and uses it alongside everything else they know to continue or adjust treatment.

Who it helps

Patients

Less time on treatments that aren't working, and a quicker path to ones that might.

Oncologists

Regular, objective feedback on whether a treatment is working, between scheduled scans.

Hospitals and health systems

Response monitoring that uses existing ultrasound capacity rather than scarce MRI and CT time.

Drug developers

Earlier, quantitative signals of how tumors respond while new therapies are being developed.

Where we're heading

Every patient on cancer treatment should know early whether it is working, wherever they are treated.

By making ultrasound a reliable measure of treatment response, we aim to help oncologists reach the right treatment sooner, spare patients therapies that aren't helping, and bring this kind of precision to places without easy access to MRI or CT.

  • Make frequent, objective response monitoring part of routine cancer care
  • Begin with breast cancer, then extend to liver cancer, liver metastases and other solid tumors
  • Fit into the equipment and workflows clinicians already use
  • Reach clinics and communities far from major imaging centers

Talk to us

We'd like to hear from oncologists, hospitals, imaging companies and life-science partners who share this goal.

Email Curesign
info@curesign.com